Skip to content

Air-Q Intubating Laryngeal Airway Versus the Laryngeal Mask Airway (LMA)-Proseal

The Air-Q Intubating Laryngeal Airway Versus the LMA-Proseal: A Prospective, Randomized Trial of Airway Seal Pressure

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01328405
Enrollment
100
Registered
2011-04-04
Start date
2009-10-31
Completion date
2010-04-30
Last updated
2015-10-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Difficult Airway, Anesthesia; Functional

Brief summary

Introduction: The air-QⓇ Intubating Laryngeal Airway (ILA) is a newer supraglottic airway. It is approved for use as a primary airway and as an aid for intubation in situations of anticipated or unanticipated difficult airways. A unique feature of this device as compared to other airways on the market is the size of the inner diameter (ID) and length of its airway tube. Direct placement of tracheal tubes \> 7.5 mm ID through the airway tube is possible. The ProSealTM LMA is considered the gold standard for supraglottic devices with respect to airway seal pressure. On average, it is reported to be approximately 28 cmH2O. This is significantly higher than that of the first generation LMA, the LMA-ClassicTM, which has a maximum seal pressure of 20 cmH2O, but averages 16-18 cmH2O in actual practice. In this study the investigators aim to test whether the air-QⓇ creates an airway seal pressure that is similar to the LMA-ProSealTM, whether the position of the air-QⓇ in relation to the vocal cords, as assessed by fiberoptic endoscopy, is similar to that of the LMA-ProSealTM and whether airway morbidity is similar between the air-QⓇ and the LMA-ProSealTM.

Detailed description

Introduction: The air-QⓇ Intubating Laryngeal Airway (ILA) (Mercury Medical, Clearwater, Fl.) is a newer supraglottic airway. It is approved for use as a primary airway and as an aid for intubation in situations of anticipated or unanticipated difficult airways. A unique feature of this device as compared to other airways on the market is the size of the inner diameter (ID) and length of its airway tube. Direct placement of tracheal tubes \> 7.5 mm ID through the airway tube is possible. The ProSealTM LMA (LMA North America, La Jolla, CA) is considered the gold standard for supraglottic devices with respect to airway seal pressure. On average, it is reported to be approximately 28 cmH2O. This is significantly higher than that of the first generation LMA, the LMA-ClassicTM, which has a maximum seal pressure of 20 cmH2O, but averages 16-18 cmH2O in actual practice. Pilot data from 50 insertions of the air-QⓇ at our institution places the device intermediate to the two aforementioned LMAs with regard to seal pressure, with a mean seal pressure of 23 (12-30) cmH2O. Specific Aims: 1. To test whether the air-QⓇ creates an airway seal pressure that is similar to the LMA-ProSealTM. 2. To test whether the position of the air-QⓇ in relation to the vocal cords, as assessed by fiberoptic endoscopy, is similar to that of the LMA-ProSealTM. 3. To test whether airway morbidity is similar between the air-QⓇ and the LMA-ProSealTM Study design: Prospective, single-center, randomized, controlled trial Methods: The patient will be met in the pre-operative area by the attending anesthesiologist, who interviews and examines the patient. A full explanation of the general anesthetic, including risks and benefits, will be given and informed consent obtained. An intravenous catheter will be placed and patients will be premedicated as needed at the discretion of the attending anesthesiologist. In the operating room, the patient will undergo standard monitoring per established American Society of Anesthesiology (ASA) guidelines. After a period of breathing 100% oxygen by facemask, anesthesia will be induced intravenously typically with fentanyl 0.5-1.5 mcg.kg -1 (a fast acting narcotic) and propofol (a potent sedative/amnestic agent) 2-3 mg.kg -1. After eyelash reflex is lost (i.e. the patient is asleep and not breathing), the patient will typically be ventilated with a facemask to demonstrate the patency of the airway. The LMA will then be placed using a standard technique. The cuff of the LMA will be inflated and the adequacy of placement assessed by presence of end-tidal carbon dioxide and adequate chest rise. The airway seal pressure will then be assessed by closing the APL valve on the anesthesia machine with a fresh gas flow of 5 liters/minute until an audible leak is observed. A stethoscope will be placed over the stomach while the valve is closed to listen for gastric insufflation. Administration of other anesthetic medication or muscle relaxants is at the discretion of the anesthesiologist and based on their clinical judgment and/or at the request of the surgeon. The anesthesia provider will not be blinded and will have access to all the monitors. The study deviates from routine care in that the choice of which LMA to use will be randomized by opening a sealed envelope prior to the start of the case. In addition, once the LMA has been placed and secured and the patient is stable from an anesthetic point of view, a flexible fiberoptic camera will be place into the airway tube of the LMA and the view of the patient's vocal cords in relation to the cuff of the LMA will be assessed. At the conclusion of the case, when the patient is breathing on their own and is awake enough, as judged by the anesthesia provider, the LMA will be removed, as would be otherwise done as standard of care. The study LMA will be examined by a data collector for the presence of grossly visible blood or bile, and its presence or absence will be recorded. In the recovery area, once the patient is fully awake, as judged by the recovery staff, an observer will administer a standard oral questionnaire to the patient to determine if a sore throat, difficulty swallowing, or difficulty speaking is present. The patient will be called 24 hours later by the data collector and the same questionnaire will be administered.

Interventions

Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.

Sponsors

University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who are 18 years or greater may be included if they presenting for any elective surgery or procedure to take place in any anesthetic location and require placement of a LMA for their surgery or procedure.

Exclusion criteria

* non-English speaking * pregnant * are a minor * are a prisoner * have impaired decision-making capacity or any condition for which the primary anesthesia team deems intubation with a tracheal tube to be necessary

Design outcomes

Primary

MeasureTime frameDescription
Airway Seal PressureIntraoperative (day 1)The airway seal pressure will then be assessed by closing the APL valve on the anesthesia machine with a fresh gas flow of 5 liters/minute until an audible leak is observed.

Secondary

MeasureTime frameDescription
Grossly Visible Blood or Bile on LMAUpon LMA removalAt the conclusion of the case, when the patient is breathing on their own and is awake enough, as judged by the anesthesia provider, the LMA will be removed, as would be otherwise done as standard of care. The study LMA will be examined by a data collector for the presence of grossly visible blood or bile, and its presence or absence will be recorded.
Glottic ViewIntraoperative (day 1)Once the LMA has been placed and secured and the patient is stable from an anesthetic point of view, a flexible fiberoptic camera will be place into the airway tube of the LMA and the view of the patient's vocal cords in relation to the cuff of the LMA will be assessed.
Airway PathologyPostoperative (day 1) in recovery roomIn the recovery area, once the patient is fully awake, as judged by the recovery staff, an observer will administer a standard oral questionnaire to the patient to determine if a sore throat is present.

Countries

United States

Participant flow

Participants by arm

ArmCount
Air-Q LMA
Air-QⓇ intubating laryngeal mask (Mercury Medical, Clearwater, Fl.)
52
Proseal LMA
LMA-Proseal TM (LMA North America, San Diego, Ca.)
48
Total100

Baseline characteristics

CharacteristicProseal LMAAir-Q LMATotal
Age, Categorical
<=18 years
1 Participants0 Participants1 Participants
Age, Categorical
>=65 years
2 Participants1 Participants3 Participants
Age, Categorical
Between 18 and 65 years
45 Participants51 Participants96 Participants
Age, Continuous39 years
STANDARD_DEVIATION 14
39 years
STANDARD_DEVIATION 12
39 years
STANDARD_DEVIATION 13
Region of Enrollment
United States
48 participants52 participants100 participants
Sex: Female, Male
Female
23 Participants24 Participants47 Participants
Sex: Female, Male
Male
25 Participants28 Participants53 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 520 / 48
serious
Total, serious adverse events
0 / 520 / 48

Outcome results

Primary

Airway Seal Pressure

The airway seal pressure will then be assessed by closing the APL valve on the anesthesia machine with a fresh gas flow of 5 liters/minute until an audible leak is observed.

Time frame: Intraoperative (day 1)

ArmMeasureValue (MEAN)Dispersion
Air-Q LMAAirway Seal Pressure30 cmH2OStandard Deviation 7
Proseal LMAAirway Seal Pressure30 cmH2OStandard Deviation 6
Secondary

Airway Pathology

In the recovery area, once the patient is fully awake, as judged by the recovery staff, an observer will administer a standard oral questionnaire to the patient to determine if a sore throat is present.

Time frame: Postoperative (day 1) in recovery room

ArmMeasureValue (NUMBER)
Air-Q LMAAirway Pathology24 participants
Proseal LMAAirway Pathology18 participants
Secondary

Airway Pathology

The patient will be called 24 hours later by the data collector who will administer a standard oral questionnaire to the patient to determine if a sore throat is present.

Time frame: Postoperative Day Two

ArmMeasureValue (NUMBER)
Air-Q LMAAirway Pathology21 participants
Proseal LMAAirway Pathology10 participants
Secondary

Glottic View

Once the LMA has been placed and secured and the patient is stable from an anesthetic point of view, a flexible fiberoptic camera will be place into the airway tube of the LMA and the view of the patient's vocal cords in relation to the cuff of the LMA will be assessed.

Time frame: Intraoperative (day 1)

ArmMeasureValue (NUMBER)
Air-Q LMAGlottic View41 participants with grade 1 glottic view
Proseal LMAGlottic View29 participants with grade 1 glottic view
Secondary

Grossly Visible Blood or Bile on LMA

At the conclusion of the case, when the patient is breathing on their own and is awake enough, as judged by the anesthesia provider, the LMA will be removed, as would be otherwise done as standard of care. The study LMA will be examined by a data collector for the presence of grossly visible blood or bile, and its presence or absence will be recorded.

Time frame: Upon LMA removal

ArmMeasureValue (NUMBER)
Air-Q LMAGrossly Visible Blood or Bile on LMA10 participants
Proseal LMAGrossly Visible Blood or Bile on LMA4 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026